Understanding how obesity-related factors influence prostate cancer progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters in prostate cancer tissues from patients with varying body mass indices (BMI). It aims to characterize the immune cell presence in these tumors and assess how lactate accumulation relates to changes in the tumor immune environment and oncogenic pathways. By comparing severely overweight/obese patients to those with normal weight, the study seeks to uncover metabolic influences on cancer progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* affected by prostate cancer

Exclusion Criteria:

\-

Where it's running

• IRCCS Cà Granda Ospedale Maggiore Policlinico Milano
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Giancarlo Albo, MD,
• Email: giancarlo.albo@policlinico.mi.it
• Phone: 00390255034501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy

  This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT06957691

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Lower-dose radiation to parts of the prostate for some men with prostate cancer

  This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07635238

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

• Using AI to help find prostate cancer on MRI

  This study tests whether an AI software can help doctors find suspicious lesions on prostate MRI in men aged 55–80 who are having a pre-biopsy MRI and planned prostate biopsy.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07084779

• Two-fraction radiotherapy for localized prostate cancer

  This study is testing if giving radiotherapy in just two sessions instead of five can effectively treat localized prostate cancer while causing fewer side effects for patients.

  Recruiting UMC Utrecht · Utrecht · NCT06518226

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.